Key Highlights

  • H1 2026 annual Recurring Revenue reached £28.8 million, up 75% year-on-year (69% at constant currency).
  • Group revenue rose 20% to £17.5 million, with adjusted EBITDA up to £1.1 million from £0.1 million.
  • Net revenue retention climbed to 146% while gross churn fell to 9% from 19% a year earlier.
  • The order book stood at £43.7 million, giving 91% revenue visibility against FY2026 consensus.
  • Diaceutics now works with 18 of the top 20 global pharmaceutical companies across 99 therapeutic brands.

The LSE-listed diagnostics data firm behind the DXRX platform reported annual recurring revenue up 75% in its latest trading update, alongside falling churn and a swelling order book. Here is what the numbers actually show.

Diaceutics (LSE:DXRX) has spent years trying to solve a stubborn problem in medicine: pharmaceutical companies develop precision therapies that only work for patients with a specific biomarker, yet the diagnostic testing needed to identify those patients is frequently missed, delayed or misread. Its DXRX platform sells data, analytics and advisory services to pharma companies commercialising targeted drugs. In a 29 July 2026 trading update, the company said annual recurring revenue (ARR) had grown 75% period-on-period in H1 2026, a figure that, on verification, stacks up against its own reported comparatives.

What Happened

Diaceutics' H1 2026 trading update, headlined "75% ARR Growth Drives Revenue & Profit Visibility," disclosed ARR of £28.8 million at the half-year, against £16.4 million a year earlier — a 75% increase, or 69% at constant currency, and up 45% since December 2025 alone. Group revenue for the six months rose 20% to £17.5 million (22% constant currency), continuing a run management says represents a three-year compound annual growth rate of 21%. Adjusted EBITDA reached £1.1 million, up from £0.1 million a year earlier, with gross Margin expanding to 87% from 83%. The update followed a 15 January 2026 full-year statement in which Diaceutics said it had returned to profit after tax for FY2025, with adjusted EBITDA expected to exceed the prior consensus of £7.1 million.

Why It Matters

The ARR figure matters because it measures the contracted, subscription-like portion of Diaceutics' Business — the part investors typically prize most in data companies because it is more predictable than one-off advisory fees. A company converting more revenue into recurring, renewable contracts should become easier to forecast and more resilient to any single client pulling back. Diaceutics describes a multi-year push toward "a high-quality ARR model with improving margins," built around enterprise-wide agreements spanning multiple drug brands with a single pharma customer, rather than one-off engagements tied to a single product launch.

Latest Financial and Operational Performance

The H1 2026 update showed net revenue retention (NRR) — a measure of how much revenue existing customers generate year-on-year, including upsells and losses — at 146%, up from 118% in H1 2025. Gross churn, the rate at which contracted ARR is lost, fell to 9% from 19%, evidence the enterprise-wide contract structure is proving stickier than legacy project work. The order book stood at £43.7 million, up from £31.7 million, with £15.7 million already contracted for delivery in H2 2026. Diaceutics said this gave it 91% visibility, including weighted pipeline, against median analyst consensus for FY2026 revenue of £46.7 million. The Balance Sheet remained debt-free, with cash of £8.1 million (up from £7.3 million at 31 December 2025) and a further £2.0 million undrawn Facility . Detailed interim results are due in late September 2026.

Key Numbers

  • H1 2026 ARR: £28.8 million, up 75% year-on-year (69% constant currency)
  • H1 2026 revenue: £17.5 million, up 20% (22% constant currency)
  • Net revenue retention: 146% (H1 2025: 118%)
  • Gross churn: 9% (H1 2025: 19%)
  • Adjusted EBITDA: £1.1 million (H1 2025: £0.1 million); gross margin 87% (H1 2025: 83%)
  • Order book: £43.7 million (H1 2025: £31.7 million); cash £8.1 million, no Debt
  • FY2025 (full year): revenue £38.5 million (+20%); ARR £20.3 million+ (+21%); returned to profit after tax

Growth Opportunities

Diaceutics' pitch to pharma clients is that it can help them commercialise precision therapies faster by identifying where testing gaps are costing them patients — and, by extension, revenue. The company said it now works with 18 of the top 20 global pharmaceutical companies, supporting 99 therapeutic brands across 54 customers on a trailing-twelve-month basis, up from 95 brands at the end of 2025. Enterprise-wide agreements, which lock in a customer across multiple brands, generated £13.0 million of ARR by FY2025 year-end across ten live engagements spanning 36 brands. The group also disclosed a second commercialisation Partnership for its PMx offering with a US biotech, following expansion of an earlier such deal, and opened a US headquarters in January 2025, signalling intent to deepen its presence in the world's largest pharmaceutical market. Management has also pointed to increased use of artificial intelligence across the business as a driver of margin improvement, alongside the platform's underlying data network, which draws on laboratory information from more than 50 countries.

Risks Investors Should Know

Diaceutics remains a small-cap AIM stock with a concentrated customer base: a large share of revenue comes from a limited number of major pharmaceutical relationships, and the loss or delay of even one enterprise contract could move the numbers materially. Revenue visibility of 91% toward consensus, while high, implies roughly a tenth of expected FY2026 revenue is not yet firmly contracted. Currency exposure is meaningful, given the gap between reported and constant-currency growth rates in every recent update, reflecting significant US dollar-denominated business. Churn has improved markedly but has not been eliminated, and net revenue retention above 140% — unusually high for the sector — needs to be sustained over further periods before it can be treated as a durable trend rather than one strong half. Pharma clients' own budget cycles, and any broader pullback in industry commercialisation spending, are also outside Diaceutics' control.

What to Watch Next

The next formal checkpoint is the full interim results release, expected late September 2026, which should provide more detail behind the July trading update. Investors will also watch whether the £15.7 million of contracted H2 2026 revenue converts on schedule, whether churn continues to fall from its improved 9% level, and whether Diaceutics signs further enterprise-wide or PMx partnership agreements, particularly in the US.

Outlook

Diaceutics' latest update gives genuine substance to the idea that its business model is shifting from project-based consulting toward a more predictable, subscription-style structure. The 75% ARR growth figure is verifiable in the company's own disclosures, and comes with corroborating detail — falling churn, rising retention and an expanding order book — rather than standing alone. Even so, the business remains reliant on a small number of large pharma relationships, and the coming interim results will be the first real test of whether this half's momentum holds.